- Home
- SKYE vs VGI Comparison
SKYE vs VGI Comparison
Compare SKYE & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- VGI
- Stock Information
- Founded
- SKYE 2012
- VGI 2012
- Country
- SKYE United States
- VGI United States
- Employees
- SKYE N/A
- VGI N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- VGI Investment Managers
- Sector
- SKYE Health Care
- VGI Finance
- Exchange
- SKYE Nasdaq
- VGI Nasdaq
- Market Cap
- SKYE 80.7M
- VGI 91.4M
- IPO Year
- SKYE N/A
- VGI N/A
- Fundamental
- Price
- SKYE $2.95
- VGI $7.89
- Analyst Decision
- SKYE Buy
- VGI
- Analyst Count
- SKYE 6
- VGI 0
- Target Price
- SKYE $18.67
- VGI N/A
- AVG Volume (30 Days)
- SKYE 169.1K
- VGI 46.0K
- Earning Date
- SKYE 02-13-2025
- VGI 01-01-0001
- Dividend Yield
- SKYE N/A
- VGI 12.66%
- EPS Growth
- SKYE N/A
- VGI N/A
- EPS
- SKYE N/A
- VGI N/A
- Revenue
- SKYE N/A
- VGI N/A
- Revenue This Year
- SKYE N/A
- VGI N/A
- Revenue Next Year
- SKYE N/A
- VGI N/A
- P/E Ratio
- SKYE N/A
- VGI N/A
- Revenue Growth
- SKYE N/A
- VGI N/A
- 52 Week Low
- SKYE $2.31
- VGI $6.68
- 52 Week High
- SKYE $19.41
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- SKYE 47.80
- VGI 57.32
- Support Level
- SKYE $2.53
- VGI $7.65
- Resistance Level
- SKYE $4.25
- VGI $7.74
- Average True Range (ATR)
- SKYE 0.43
- VGI 0.09
- MACD
- SKYE 0.10
- VGI 0.02
- Stochastic Oscillator
- SKYE 28.84
- VGI 91.30
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objectives by capitalizing on opportunities across undervalued areas of the global bond markets.